My Watchlist

Top Indices

NASDAQ Composite

Standard & Poors 500

My Portfolio

Eli Lilly (NY:LLY)

1,443.50 +16.22 (+1.14%)

Official Closing Price Updated: 7:00 PM EST, Nov 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

LifeMD: 3 Key Takeaways for Long-Term Investors ↗

November 14, 2026

Lower acquisition costs and flat overhead could let LifeMD keep more of each subscriber's revenue as patient volume grows.

Via The Motley Fool

Topics Earnings

Firefly Aerospace vs. Redwire: Which Industrials Stock Is a Better Buy for 2027? ↗

November 14, 2026

Firefly's $1.4 billion backlog and Redwire's 45.8% revenue growth point to very different bets, and the valuation gap may be the deciding factor.

Via The Motley Fool

Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028 ↗

November 13, 2026

Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price.

Via The Motley Fool

What LifeMD (LFMD) Said on Its Q3 Earnings Call ↗

November 12, 2026

LifeMD (NASDAQ:LFMD) lowered its full-year revenue and adjusted EBITDA outlook after third-quarter sales fell short of its forecast, as the virtual healthcare company cut marketing spending and took...

Via MarketBeat

Topics Earnings

Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It ↗

November 12, 2026

The world's largest healthcare company is making shrewd investments in its future.

Via The Motley Fool

Topics Artificial Intelligence

More Good News for Eli Lilly Sends the Stock Even Higher ↗

November 12, 2026

Lilly's experimental GLP-1 is effective in treating osteoarthritic knee pain.

Via The Motley Fool

Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off ↗

November 12, 2026

Hims & Hers stock sank after a Q3 earnings and revenue miss, lower EBITDA guidance, subscriber declines, and an expanding FTC lawsuit over privacy and billing practices.

Via MarketBeat

Topics Earnings Lawsuit

JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now? ↗

November 11, 2026

Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.

Via The Motley Fool

Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner? ↗

November 11, 2026

These drugmakers offer very different risk-reward profiles.

Via The Motley Fool

S&P 500 After-Hours Movers: MNST, RDDT Among Gainers; VEEV, LLY Among Losers in Latest Session ↗

November 11, 2026

Via Chartmill

Topics Stocks

Which Is the Better Buy: iShares’ Pharma ETF IHE or First Trust’s Biotech Fund FBT? ↗

November 11, 2026

iShares offers lower fees and smoother returns, while First Trust provides concentrated biotech exposure with higher growth potential.

Via The Motley Fool

Topics Derivatives ETFs

Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027? ↗

November 11, 2026

Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.

Via The Motley Fool

A Billionaire Investor Links Cancer Treatment and Wireless Technology as AI Pharmaceutical Testing Gains Ground

November 11, 2026

Via AB Newswire

Topics Artificial Intelligence

My Forever Portfolio: 4 Spectacular Stocks You Can Buy Now and Never Sell ↗

November 11, 2026

It takes a slightly different mindset when you're investing for a longer time horizon.

Via The Motley Fool

Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy? ↗

November 10, 2026

These stocks have been going in different directions over the past year, but that trend may not necessarily continue.

Via The Motley Fool

Hims & Hers: 3 Key Takeaways for Long-Term Investors ↗

November 10, 2026

Management is betting that a lighter marketing push now sets Hims & Hers up for the January weight-loss surge, but it's unclear whether lost subscribers will return.

Via The Motley Fool

Topics Earnings

This Growth ETF Has Crushed the S&P 500 Since 2004. Here's Why It's Still a Buy. ↗

November 10, 2026

The upside outweighs the inevitable volatility.

Via The Motley Fool

Topics ETFs Stocks

Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy? ↗

November 10, 2026

The healthcare stock has soared past the S&P 500 this year as its results have been strong in recent quarters.

Via The Motley Fool

Topics Stocks

Want to Escape the AI Sell-Off? This ETF Offers a Surprising Alternative ↗

November 09, 2026

As tech stocks sell off, the ProShares S&P 500 ex-Technology ETF (SPXT) offers reduced AI exposure, but its mega-cap holdings, light liquidity, and trailing returns temper its appeal.

Via MarketBeat

Topics Artificial Intelligence ETFs Stocks

Gabelli Releases Agenda for 8th Annual Healthcare Symposium

November 09, 2026

From Gabelli Funds

Via GlobeNewswire

Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide. ↗

November 09, 2026

The companies are competing in the weight loss drug market.

Via The Motley Fool

New Independent Research Hub Launches for Eloralintide, Lilly’s Investigational Amylin Agonist

November 09, 2026

Via Press Release Distribution Service

Topics Supply Chain

3 Super Growth Stocks to Buy Hand Over Fist If the Stock Market Crashes ↗

November 08, 2026

One of these stocks is up 265% over the past year -- and its shares don't seem wildly overvalued, either.

Via The Motley Fool

Topics Economy

Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now? ↗

November 08, 2026

Novo Nordisk is looking to build a volume-driven business, but the successful launch of the Wegovy pill is just the first step.

Via The Motley Fool

Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials ↗

November 07, 2026

Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.

Via The Motley Fool

Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy? ↗

November 07, 2026

The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast.

Via The Motley Fool

IYH and XBI: Two Distinct Paths to Investing in Healthcare ↗

November 07, 2026

XBI delivered stronger 1-year returns at 45%, but IYH's diversified portfolio weathered volatility far better, with a maximum drawdown of just 17.9% versus 53.2%.

Via The Motley Fool

Topics ETFs

Certified PEP MEX Expands Its Reach in Mexico With Two New Research Peptide Websites

November 07, 2026

Via Press Release Distribution Service

Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence ↗

November 06, 2026

Eli Lilly could thrive even as competition in the weight-loss market intensifies.

Via The Motley Fool

Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly ↗

November 06, 2026

Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.